• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Imaging and Intervention

Computer-extracted MRI features help distinguish benign from malignant prostate lesions

byDavid WangandDylan Wolman
July 26, 2015
in Imaging and Intervention, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a retrospective review of prostate magnetic resonance imaging (MRI) and corresponding prostatectomy pathology specimens from 70 patients with prostate cancer, use of only the most discriminatory computer-extracted imaging features differentiating benign disease from cancer resulted in improved diagnostic capabilities.

2. Benign prostatic hyperplasia (BPH) was best discriminated from cancer using high-b-value diffusion-weighted imaging, while high grade cancer was best identified using the apparent diffusion coefficient.

Evidence Rating Level: 3 (Average)

Study Rundown: Recent advancements in magnetic resonance imaging technologies, such as the development of multi-parametric MRI has demonstrated improved accuracy in the diagnosis and staging of prostate cancer. However, the use of image scoring systems such as the Prostate Imaging Reporting and Data System (PI-RADS) may lead to over-diagnosis of prostate cancer, particularly given the similar appearance of noncancerous mimics of prostate cancer such as prostatic intraepithelial neoplasia (PIN), BPH, prostatic atrophy, and prostate inflammation. The purpose of this study was to determine which computer-extracted features are best able to distinguish between benign and malignant prostate lesions. The authors retrospectively analyzed prostatectomy specimens from 70 men that underwent radical prostatectomy and had pre-operative multi-parametric MRI. The known areas of prostate cancer and non-malignant disease were co-registered to their corresponding images on multi-parametric MRI. Subvisual image features were algorithmically extracted to generate edge enhancement or highlight intensity homogeneity, among other textural features drawn from source images in an effort to focus attention on otherwise subtle differences in the appearance of different lesion types. Computer-extracted features were subsequently analyzed and associated with the respective pathological findings.

At the conclusion of the study, the authors found that each benign prostate disease-type analyzed (BPH, PIN, atrophy, and inflammation) had a distinguishing feature on multi-parametric MRI that may help to distinguish it from malignant prostatic adenocarcinoma. Key among these were the findings that BPH was best discriminated from cancer using high-b-value diffusion-weighted imaging, while inflammatory lesions were generally highly focal on contrast-enhanced images, and high-grade tumors were best differentiated using the apparent diffusion coefficient. The results of this study support the use of these computer extracted-MR to distinguish benign from malignant prostatic disease, and even found that using only the most useful differentiating feature to differentiate benign from malignant disease was more effective than using all available features. However, the study is limited by the small sample site and the lack of similar supporting data among other studies. Additional large trials are required to confirm these associations and more specifically delineate which features would be best used in daily practice, as would a trial that compares the use of these computer-extracted features to the diagnostic accuracy of simply reading of multi-parametric MRI images by an experienced radiologist.

Click to read the study in Radiology

RELATED REPORTS

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

Stockholm3 outperforms PSA for detecting significant prostate cancer 

Pfizer’s Talzenna combo significantly delays prostate cancer progression

Relevant Reading: Prostate Cancer: The European Society of Urogenital Radiology Prostate Imaging Reporting and Data System Criteria for Predicting Extraprostatic Extension by Using 3-T Multiparametric MR Imaging

In-Depth [retrospective cohort]: This study is a retrospective review of a cohort of 70 patients that underwent radical prostatectomy with pre-operative 3-T multi-parametric MRI. Sequences in the MRI included T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced imaging. Each prostatectomy specimen was histologically investigated and digitized in consecutive sections. Each section was annotated for the presence of adenocarcinoma, BPH, PIN, atrophy, or inflammation by an experienced pathologist. The digitized slides were then co-registered with their corresponding area on the multi-parametric MRI images for direct comparison to known pathologic foci. At the conclusion of the study, each individual benign prostatic disease had a unique MR-derived feature that distinguished it from prostate cancer, which are as follows: BPH: lesions observed on high-b-value image; atrophy: focal lesion appearance on dynamic contrast-enhanced images; PIN: ADC values; inflammation: lesion focality on T2-weighted images. The accuracy of distinguishing specific benign lesions compared to cancer was improved when using only the single most useful differentiating factor computer-extracted feature (AUC = 0.70) versus grouping all noncancerous findings together compared to cancer (AUC = 0.62).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Magnetic Resonance Imaging (MRI)prostate cancer
Previous Post

Increased rates of hospitalization among survivors of young adult malignancies

Next Post

Bisphosphonate treatment reduces breast cancer recurrence in the bones of post-menopausal women

RelatedReports

Radiation plus hormone therapy may improve prostate cancer survival
Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Oncology

Stockholm3 outperforms PSA for detecting significant prostate cancer 

June 22, 2026
Radiation plus hormone therapy may improve prostate cancer survival
Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Next Post
Romosozumab significantly increases bone mineral density in postmenopausal women

Bisphosphonate treatment reduces breast cancer recurrence in the bones of post-menopausal women

Physician gaps in maternal infant care counseling

Physician gaps in maternal infant care counseling

Validation of prediction tool for pediatric head trauma etiology

Validation of prediction tool for pediatric head trauma etiology

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind August 17, 2026
  • Melatonin use is associated with lower proportions of rapid eye movement sleep in children
  • Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.